Januvia Pancreatic Cancer Lawsuits 2026: MDL 2452, the Revival, and Who Can Still File
Nearly 1,000 lawsuits claim that Januvia and related diabetes drugs caused pancreatic cancer and pancreatitis. A federal judge dismissed them all in 2015, an appeals court revived them in 2017, and no global settlement has been announced. The cases remain individual claims, and the question for patients in 2026 is whether their own medical history fits them.
Januvia, known generically as sitagliptin, treats type 2 diabetes by helping the body manage blood sugar. It belongs to a family called incretin mimetics — drugs that mimic gut hormones which prompt the pancreas to release insulin after eating. The lawsuits claim manufacturers knew of a pancreatic risk, failed to warn doctors and patients adequately, and left the words pancreatic cancer off the labels. The manufacturers dispute that the drugs cause pancreatic cancer at all.
Key Facts
- Nearly 950 lawsuits over Januvia, Janumet, Byetta, and Victoza were consolidated in federal court in California as MDL No. 2452.
- In May 2013, the FDA issued a safety communication linking incretin mimetics to pancreatic disease and announced an investigation into pancreatic cancer.
- In November 2015, U.S. District Judge Anthony J. Battaglia dismissed all the MDL cases on preemption grounds.
- In December 2017, the Ninth Circuit Court of Appeals overturned that dismissal and reinstated the cases.
- No global settlement has been announced for these pancreatic-cancer claims, and each case remains an individual lawsuit.
What Januvia Is — and What It Is Accused Of
An incretin mimetic copies the action of incretins, hormones released by the gut after a meal that signal the pancreas to produce insulin. Januvia and its combination form Janumet, made by Merck, are DPP-4 inhibitors, a subgroup that prolongs incretin action; Byetta, from Amylin and Eli Lilly, and Victoza, from Novo Nordisk, stimulate the same system more directly. All four appear in the same consolidated litigation because the complaints allege the same core wrong: that the drugs increased the risk of pancreatitis — inflammation of the pancreas — and pancreatic cancer, and that the companies concealed that risk to avoid delaying or losing FDA approval. The companies deny the drugs cause pancreatic cancer.
The FDA Warning That Started the Lawsuits
In May 2013, the FDA issued a safety communication linking incretin mimetics to serious pancreatic complications and announced an investigation into a possible pancreatic-cancer link. It did not declare the drugs unsafe, but it gave plaintiffs a public document connecting the drug class to the disease at the heart of their cases. Lawsuits filed in state courts across seven states accumulated, and in August 2013 the Judicial Panel on Multidistrict Litigation transferred the first 53 cases into a single federal proceeding. The human stories are stark. Guy Riley of Maryland sued after his wife Kathleen, prescribed Januvia and Byetta from 2005, was diagnosed with pancreatic cancer in 2009 and died later that year. These are allegations, not court findings, but they explain why families pursued cases for more than a decade.
MDL 2452: Nearly 1,000 Cases in One Courtroom
A multidistrict litigation, or MDL, gathers federal lawsuits sharing common facts before one judge for pretrial proceedings, while each plaintiff keeps an individual case and right to compensation. MDL No. 2452, In Re: Incretin Mimetics Products Liability Litigation, went to the Southern District of California, where shared questions could be litigated once. The central fight was not about medicine at first. It was about preemption, the doctrine under which federal law overrides state-law claims in federally regulated areas. The manufacturers argued they could not be liable for failing to warn because the FDA would never have approved such a label change.
Dismissed in 2015, Revived in 2017
In November 2015, Judge Battaglia agreed with the manufacturers. He found by clear evidence that the FDA would have rejected a pancreatic-cancer reference in product labeling, dismissed all the cases, disqualified the plaintiffs' expert, Dr. Thomas Fleming, and declined to permit a substitute. It was a total defeat on a ground unrelated to whether any patient was harmed. They appealed in September 2016, arguing the judge had misunderstood the Supreme Court's preemption law, particularly Wyeth v. Levine, which holds that manufacturers may strengthen safety language without prior FDA approval. In December 2017, the Ninth Circuit agreed: the judge had improperly limited discovery relevant to any causal connection, and should not have disqualified Fleming. The dismissal was overturned. That revival is why the litigation still matters in 2026 — not a finding that Januvia causes pancreatic cancer, only that plaintiffs deserve the chance to prove their claims. Related drug classes have separate proceedings: GLP-1 gastroparesis claims concern stomach paralysis, and Ozempic gastroparesis claims sit in a different MDL in Pennsylvania.
Who Benefits From This — and Who Does Not
The people who may benefit are specific. A patient who took Januvia, Janumet, Byetta, or Victoza and was later diagnosed with pancreatic cancer or pancreatitis has the fact pattern these cases were built around, especially with prescription records showing sustained use before diagnosis. Families of patients who died of pancreatic cancer after taking one of these drugs may also have wrongful-death claims, as the Riley case shows. Patients still taking one benefit differently: the public record details what was known and when. Who does not benefit is just as clear. Patients who took these drugs without developing pancreatic disease have no injury to claim. Patients diagnosed before ever taking an incretin mimetic cannot fit the causation timeline. And patients whose injuries are stomach paralysis or vision loss belong in different litigations; a vision-loss claim follows an entirely different medical theory. Filing in the wrong litigation wastes the statute of limitations — each state's deadline for bringing a claim — and that deadline is the most common reason sympathetic cases die unfiled.
What a Claim Requires in 2026
A viable Januvia claim rests on three documented pillars. First, prescription history: pharmacy records showing the drug, dates, and duration of use, ideally predating diagnosis. Second, diagnosis: medical records confirming pancreatic cancer or pancreatitis, with pathology and treatment history. Third, timing and exclusion: a timeline placing drug use before disease, and evidence addressing other risk factors — smoking, chronic pancreatitis, family history, obesity — which the defense will raise in every case. Defective-drug attorneys typically work on a contingency fee, collecting a share of any successful recovery, commonly around one-third, and nothing if the case fails. Two cautions belong in any honest account. Causation remains contested, and no court has delivered a final verdict establishing that these drugs cause pancreatic cancer. And Januvia has not been withdrawn over these claims, so patients taking it should not stop on litigation news alone — that decision belongs to the patient and the prescribing doctor.
This article is general information, not legal or medical advice. For an individual case, consult a licensed attorney; for treatment decisions, consult your doctor. You can also follow Problem Solved for plain-language explanations of money and legal questions.
Frequently Asked Questions
Who benefits from the Januvia pancreatic cancer lawsuits?
Patients who took Januvia, Janumet, Byetta, or Victoza and were later diagnosed with pancreatic cancer or pancreatitis benefit most, as do families of patients who died after taking one of these drugs.
Who does not benefit from these lawsuits?
Patients who took these drugs without developing pancreatic disease, patients diagnosed before ever taking an incretin mimetic, and patients whose injuries are stomach paralysis or vision loss do not fit this litigation, because those injuries belong to different proceedings.
How do I start a Januvia claim?
Gather pharmacy and diagnosis records plus a timeline showing drug use before diagnosis, then have a defective-drug attorney review them before your state's deadline. Most offer a free review and work on contingency.
Is there a Januvia settlement I can join?
No global settlement has been announced for these pancreatic-cancer claims, so there is no settlement fund to join. Each case proceeds individually, and any recovery would come from that individual case rather than a shared fund.
Has Januvia been recalled over pancreatic cancer?
No, Januvia has not been withdrawn over these claims. The lawsuits allege a failure to warn, not a recall, and patients should discuss treatment with their prescribing doctor.
General information only — not legal or medical advice. Litigation facts are drawn from court records and the April 30, 2026 Drugwatch litigation summary cited in this article.